About This Educational Video Series

This educational video series provides expert commentary on the results and implications of Level Up, the first head-to-head trial in atopic dermatitis assessing upadacitinib (Rinvoq, AbbVie) at a starting dose of 15mg daily vs. dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals) at its labeled dose.